Skip to main content
SpringerLink
Log in

Melanom

  • Chapter
  • First Online:
Medikamentöse Tumortherapie in der Dermato-Onkologie

  • 1633 Accesses

Zusammenfassung

Melanom ist der gefährlichste Hautkrebs, der schon bei jungen Menschen auftreten kann und seit Jahrzehnten steigende Inzidenz verzeichnet (Jemal et al. 2007; Little et al. 2012). Jährlich erkranken weltweit etwa 137.000 Menschen am Melanom und 37.000 versterben an der Erkrankung (Boyle et al. 2004). Die Inzidenz liegt weltweit jährlich bei 2,3–2,6/100.000 Einwohner (Pisani et al. 2002). In Deutschland beträgt die Inzidenz 19,2/100.000 Einwohner und es verstarben 2711 Betroffene im Jahre 2010 (Statistisches Bundesamt).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G; Association Française de Chirurgie (2006) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244(4):524–35

    PubMed  Google Scholar 

  • Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY (2011) Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 29(1):49–55

    PubMed  Google Scholar 

  • Alikhan A, Ibrahimi OA, Eisen DB (2012) Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J Am Acad Dermatol 67(4):495.e1

    PubMed  Google Scholar 

  • Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP (2002) Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J 86(2):163–7

    Google Scholar 

  • Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–72

    PubMed  Google Scholar 

  • Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–16

    PubMed  CAS  Google Scholar 

  • Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 15; 22(6):1118–25

    PubMed  CAS  Google Scholar 

  • Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–206

    PubMed  Google Scholar 

  • Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe’er J (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27(4A):1897–900

    PubMed  CAS  Google Scholar 

  • Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB (2002) Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 87(8):840–5

    PubMed  CAS  Google Scholar 

  • Bedikian AY, Millward M, Pehamberger H et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24(29):4738–45

    PubMed  CAS  Google Scholar 

  • Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596–9

    PubMed  CAS  Google Scholar 

  • Boskens CJ, Goldinger SM, Loquai Cet al. (2013) The price of tumor control: An analysis of rare side effects of anti CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLOS ONE (in press)

    Google Scholar 

  • Bosserhoff AK, Küster H, Hein R (2004) Elevated MIA levels in the serum of pregnant women and of children. Clin Exp Dermatol 29(6):628–9

    PubMed  CAS  Google Scholar 

  • Boyle P, Dore J, Autier P, Ringborg U (2004) Cancer of the skin: a forgotten problem in Europe. European Society for Medical Oncology 15: 5–6

    Google Scholar 

  • Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL (2002) Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery 51:656–665

    PubMed  Google Scholar 

  • Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94:2265–2272

    PubMed  Google Scholar 

  • Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305(22):2327–34

    PubMed  CAS  Google Scholar 

  • Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83(8):1664–78

    PubMed  CAS  Google Scholar 

  • Chang J, Atkinson H, A’Hern R, Lorentzos A, Gore ME (1994) A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 30A(14):2093–5

    PubMed  CAS  Google Scholar 

  • Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745–51

    PubMed  CAS  Google Scholar 

  • Chapman P, Hauschild A, Robert C et al. for the BRIM-3 Study Group (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 364:2507–2516

    PubMed  CAS  Google Scholar 

  • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–16

    PubMed  CAS  Google Scholar 

  • Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2012) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30(5):2008–14

    PubMed  CAS  Google Scholar 

  • Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI (2006) Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106(9):2012–20

    PubMed  Google Scholar 

  • Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM 3rd, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE 2nd, Fraker DL, Tyler DS; American College of Surgeons Oncology Group Trial Z0020 (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25):4196–201

    PubMed  CAS  Google Scholar 

  • Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135–47

    PubMed  CAS  Google Scholar 

  • Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340–6

    PubMed  CAS  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–54

    PubMed  CAS  Google Scholar 

  • de Jonge MJ, Dumez H, Kitzen JJ, Beuselinck B, Verweij J, Courtney R, Battista A, Brega N, Schöffski P (2011) Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer 47(9):1328–35

    PubMed  Google Scholar 

  • Deneve JL, Choi J, Gonzalez RJ, Conley AP, Stewart S, Han D, Werner P, Chaudhry TA, Zager JS (2012) Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol 35(6):1480–7

    PubMed  Google Scholar 

  • Dietz UH, Sandell LJ (1996) Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 271: 3311–6

    PubMed  CAS  Google Scholar 

  • Douglas JG, Margolin K (2002) The treatment of brain metastases from malignant melanoma. Semin Oncol 29(5):518–24

    PubMed  Google Scholar 

  • Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16(6):471–8

    PubMed  CAS  Google Scholar 

  • Eggermont AM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40(12):1825–36

    PubMed  CAS  Google Scholar 

  • Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A (2009) Utility of adjuvant systemic therapy in melanoma. Ann Oncol 20 Suppl 6:vi30–4

    PubMed  Google Scholar 

  • Eggermont AM, Robert C (2011) New drugs in melanoma: it’s a whole new world. Eur J Cancer 47(14):2150–7

    PubMed  Google Scholar 

  • Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–19

    PubMed  CAS  Google Scholar 

  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–703

    PubMed  CAS  Google Scholar 

  • Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group (2012) Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma N Engl J Med 367:107–114

    PubMed  CAS  Google Scholar 

  • Garbe C, Eigentler TK (2007) Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17(2):117–27

    PubMed  Google Scholar 

  • Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G (2003) Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 21:520–529

    PubMed  Google Scholar 

  • Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751

    PubMed  CAS  Google Scholar 

  • Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T, Matushek P 4th, Legator M, Jacobson K, Dalton SR, Charzan S, Kolaitis NA, Guitart J, Lertsbarapa T, Boone S, LeBoit PE, Bastian BC (2009) Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 33(8):1146–56

    PubMed  Google Scholar 

  • Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126(1):154–60

    PubMed  CAS  Google Scholar 

  • Göhl J, Hohenberger W (2012) Malignes Melanom. In: Viszeralchirurgie, 9. Auflage. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R (2013) Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn 15(2):220–6

    PubMed  CAS  Google Scholar 

  • Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM (2006) The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 106(1):156–62

    PubMed  Google Scholar 

  • Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29(21):2904–9

    PubMed  CAS  Google Scholar 

  • Hamid O, Robert C, Daud A, Hodi S, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang P, Ribas A (2013) Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. NEJM 369(2):134–44

    Google Scholar 

  • Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC (2009) Osteopontin and ’melanoma inhibitory activity’: comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223(4):239–43

    PubMed  CAS  Google Scholar 

  • Hamid O, Robert C, Daud A, Hodi S, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang P, Ribas A (2013) Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. NEJM 369(2): 134-44

    Google Scholar 

  • Hartmann A, Bedenk C, Keikavoussi P, Becker JC, Hamm H, Bröcker EB (2008) Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 6(12):1053–9

    PubMed  Google Scholar 

  • Heinzerling L, Kühnapfel S, Meckbach D, Baiter M, Kaempgen E, Keikavoussi P, Schuler G, Agaimy A, Bauer J, Hartmann A, Kiesewetter F, Schneider-Stock R. Br J Cancer. 2013 May 28;108(10):2164-71. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.

    Google Scholar 

  • Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100(8):4712–7

    PubMed  CAS  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–23

    PubMed  CAS  Google Scholar 

  • Hodi F et al. (2012) J Clin Oncol 30 (suppl abstr 8507)

    Google Scholar 

  • Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–63

    PubMed  CAS  Google Scholar 

  • Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584–98

    PubMed  Google Scholar 

  • Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, Wiggins CL, Wingo PA (2011) Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol 65(5 Suppl 1):S17–25.e1–3

    PubMed  Google Scholar 

  • Kath R, Hayungs J, Bornfeld N, Sauerwein W, HHYPERLIN, Seeber S (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 72(7):2219–23

    PubMed  CAS  Google Scholar 

  • Katz HR (1981) The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int J Radiat Oncol Biol Phys 7:897–906

    PubMed  CAS  Google Scholar 

  • Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R; Dermatologic Cooperative Oncology Group (2005) Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23(35):9001–7

    PubMed  CAS  Google Scholar 

  • Kinsler VA, Chong WK, Aylett SE, Atherton DJ (2008) Complications of congenital melanocytic naevi in children: analysis of 16 years’ experience and clinical practice.Br J Dermatol 159(4):907–14

    PubMed  CAS  Google Scholar 

  • Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18(12):2444–58

    PubMed  CAS  Google Scholar 

  • Klingenstein A, Haritoglou I, Schaumberger MM, Nentwich MM, Hein R, Schaller UC (2011) Receiver operating characteristic analysis: calculation for the marker ’melanoma inhibitory activity’ in metastatic uveal melanoma patients. Melanoma Res 21(4):352–6

    PubMed  CAS  Google Scholar 

  • Knorr C, Meyer T, Janssen T, Goehl J, Hohenberger W (2005) Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 32(2):224–7

    PubMed  Google Scholar 

  • Krynitz B, Edgren G, Lindelöf B, Baecklund E, Brattstr NK, Wilczek H, Smedby KE (2012) Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-A Swedish population-based study. Int J Cancer. doi: 10.1002/ijc.27765. [Epub ahead of print]

    Google Scholar 

  • Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15(7):2589–95

    PubMed  CAS  Google Scholar 

  • Little EG, Eide MJ (2012) Update on the current state of melanoma incidence. Dermatol Clin 30(3):355–61

    PubMed  CAS  Google Scholar 

  • Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T (2012) A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res 22(6):440–6

    PubMed  CAS  Google Scholar 

  • Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD, Navarro C, Virgili G; RARECARE WG (2012) Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer 48(8):1167–75

    PubMed  CAS  Google Scholar 

  • Mangana J, Levesque MP, Karpova MB, Dummer R (2012) Sorafenib in melanoma. Expert Opin Investig Drugs 21(4):557–68

    PubMed  CAS  Google Scholar 

  • Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18(22):3782–93

    PubMed  CAS  Google Scholar 

  • Mariani P, Piperno-Neumann S, Servois V, Berry mg, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ (2009) Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol 35(11):1192–7

    PubMed  CAS  Google Scholar 

  • Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavic D, Pavlovic I, Paulin-Kosir SM, Cemazar C, O’Sullivan GC, Mir LM (2006) Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Supplements 4(11):3–13

    CAS  Google Scholar 

  • Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, Geertsen PF, Rudolf Z, O’Sullivan G, Marty M (2006) Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supplements 4(11):14–25

    CAS  Google Scholar 

  • Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158–66

    PubMed  CAS  Google Scholar 

  • Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13(1):97–103

    PubMed  CAS  Google Scholar 

  • Nashan D, Kocer B, Schiller M, Luger T, Grabbe S (2003) Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors. Dermatology 206(2):76–7

    PubMed  Google Scholar 

  • Noël G, Simon JM, Valery CA, Cornu P, Boisserie G, Ledu D, Hasboun D, Tep B, Delattre JY, Marsault C, Baillet F, Mazeron JJ (2002) Linac radiosurgery for brain metastasis of melanoma. Stereotact Funct Neurosurg 79(3-4):245–55

    PubMed  Google Scholar 

  • Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S (2006) Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17(4):578–83

    PubMed  CAS  Google Scholar 

  • Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, Lai CY, Hsu MY, Herlyn M, Stingl G, Wagner SN (2012) Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther 20(5):1056–62

    PubMed  CAS  Google Scholar 

  • Pingpank JF, Hughes MS, Alexander HR (2010) A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol 28(18 suppl):LBA8512

    Google Scholar 

  • Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97:72–81

    PubMed  CAS  Google Scholar 

  • Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ (2003) Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol 61:73–80

    PubMed  Google Scholar 

  • Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC (1999) Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86(11):2252–8

    PubMed  CAS  Google Scholar 

  • Postow MA, Carvajal RD (2012) Therapeutic implications of KIT in melanoma. Cancer J 18(2):137–41

    PubMed  CAS  Google Scholar 

  • Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG (2010) Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 21(2):409–14

    PubMed  CAS  Google Scholar 

  • Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89:1620–26

    PubMed  CAS  Google Scholar 

  • Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10(2):199–207

    PubMed  Google Scholar 

  • Reichle A, Vogt T, Coras B, Terheyden P, Neuber K, Trefzer U, Schultz E, Berand A, BrYPERLINK, Landthaler M, Andreesen R (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17(6):360–4

    PubMed  CAS  Google Scholar 

  • Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G (2004) Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 109(3):377–84

    PubMed  CAS  Google Scholar 

  • Retz M, Gschwend JE (2010) Medikamentöse Tumortherapie. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Rhodes AR, Melski JW (2982) Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr. 1982 Feb; 100(2):219–24

    Google Scholar 

  • Richardson SK, Tannous ZS, Mihm MC Jr (2002) Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol 47(1):77–90

    PubMed  Google Scholar 

  • Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R (2011) Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res 21(6):524–9

    PubMed  CAS  Google Scholar 

  • Saldanha G, Potter L, Daforno P, Pringle JH (2006) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12(15):4499–505

    PubMed  CAS  Google Scholar 

  • Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, Rassner G, Garbe C (1997) Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 80(1):60–5

    PubMed  CAS  Google Scholar 

  • Schmidt J, Bosserhoff AK (2009) Processing of MIA protein during melanoma cell migration. Int J Cancer 125(7):1587–94

    PubMed  CAS  Google Scholar 

  • Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, Foerster MH, Thiel E, Keilholz U (2006) A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 17(12):1826–9

    PubMed  CAS  Google Scholar 

  • Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK (2003) Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 44(3):1008–11

    PubMed  Google Scholar 

  • Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, Thiel E, Foerster MH, Keilholz U (2007) Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 13(4):1171–8

    PubMed  CAS  Google Scholar 

  • Selek U, Chang EL, Hassenbusch SJ 3rd, Shiu AS, Lang FF, Allen P, Weinberg J, Sawaya R, Maor MH (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59(4):1097–106

    PubMed  Google Scholar 

  • Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, Claudinot S, Okoniewski M, Beermann F, Mihic-Probst D, Moch H, Wegner M, Dummer R, Barrandon Y, Cinelli P, Sommer L (2012) Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14(8):882–90

    PubMed  CAS  Google Scholar 

  • Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439(7074):358–62

    PubMed  CAS  Google Scholar 

  • Tas F, Yasasever V, Duranyildiz D et al. (2004) Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma. Am J Clin Oncol 27: 225–8

    PubMed  CAS  Google Scholar 

  • Testori A, Rossi CR, Tosti G (2012) Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol 24(2):155–61

    PubMed  CAS  Google Scholar 

  • Trumble ER, Smith RM, Pearl G, Wall J (2005) Transplacental transmission of metastatic melanoma to the posterior fossa. Case report. J Neurosurg 103(2 Suppl):191–3

    PubMed  Google Scholar 

  • Vahrmeijer AL, van de Velde CJ, Hartgrink HH, Tollenaar RA (2008) Treatment of melanoma metastases confined to the liver and future perspectives. Dig Surg 25(6):467–72

    PubMed  Google Scholar 

  • Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602

    PubMed  CAS  Google Scholar 

  • Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O’Brien J, Bastian BC (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–9

    PubMed  CAS  Google Scholar 

  • Wang Y, Digiovanna JJ, Stern JB, Hornyak TJ, Raffeld M, Khan SG, Oh KS, Hollander MC, Dennis PA, Kraemer KH (2009) Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci USA 106(15):6279–84

    PubMed  CAS  Google Scholar 

  • Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pföhler C, Garbe C (2011) Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 60(4):487–93

    PubMed  CAS  Google Scholar 

  • Williams ML, Penella R (1994) Melanoma, melanocytic nevi, and other melanoma risk factors in children. J Pediatr 124(6):833–45

    PubMed  CAS  Google Scholar 

  • Wöll E, Bedikian A, Legha SS (1999) Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 9(6):575–81

    PubMed  Google Scholar 

  • WroŠski M, Arbit E (2000) Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 93:9–18

    PubMed  Google Scholar 

  • Zaal LH, Mooi WJ, Klip H, van der Horst CM (2005) Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands. Plast Reconstr Surg 116(7):1902–9

    PubMed  CAS  Google Scholar 

  • Zattra E, Fortina AB, Bordignon M, Piaserico S, Alaibac M (2009) Immunosuppression and melanocyte proliferation. Melanoma Res 19(2):63–8

    PubMed  Google Scholar 

  • Ziegler JC, Cooper JS (1986) Brain metastases from malignant melanoma – Conventional vs. high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys 12:1839–1842

    PubMed  CAS  Google Scholar 

Links

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Erlangen, Hautklinik, Ulmenweg 18, 91054, Erlangen, Deutschland

    Lucie Heinzerling, Anke Hartmann & Gerold Schuler

  2. Privatpraxis für Dermatologie und Ästhetische Medizin, Rzany und Hund, Ku’damm 183, 10707, Berlin, Deutschland

    Martina Hund

Authors
  1. Lucie Heinzerling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anke Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martina Hund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerold Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucie Heinzerling .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heinzerling, L., Hartmann, A., Hund, M., Schuler, G. (2014). Melanom. In: Medikamentöse Tumortherapie in der Dermato-Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-24837-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-24837-5_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-24836-8

  • Online ISBN: 978-3-642-24837-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation